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Abstract: Duloxetine is a serotonin–noradrenaline reuptake inhibitor with established efficacy for 
the short-term treatment of major depressive disorder. Efficacy in continuation treatment (greater 
than six months of continuous treatment) has been established from both open and placebo-
controlled relapse prevention and comparative studies. Seven published studies were available 
for review and showed that in both younger and older populations (aged more than 65 years) 
the acute efficacy of duloxetine was maintained for up to one year. Response to treatment was 
based on accepted criteria for remission of depression and in continuation studies remission rates 
were greater than 70%. Comparative studies showed that duloxetine was superior to placebo and 
comparable to paroxetine and escitalopram in relapse prevention. Importantly a study of dulox-
etine in patients prone to relapse of major depressive disorder showed that the medication was 
more effective than placebo in this difficult to treat population. Side effects of duloxetine during 
continuation treatment were predictable on the basis of the known pharmacology of the drug. In 
particular there were no significant life-threatening events which emerged with continued use 
of the medication. On the other hand vigilance is required since the data base on which to judge 
very rare events is limited by the relatively low exposure to the drug. Duloxetine has established 
both efficacy and safety for continuation treatment but its place as a first-line treatment of relapse 
prevention requires further experience. In particular further comparative studies against established 
agents would be useful in deciding the place of duloxetine in therapy.
Keywords: major depression, duloxetine, continuation treatment, placebo studies, relapse 
prevention, clinical trials
Introduction
It is estimated by the World Health Organization that major depression affects about 
121 million people across the globe.1 Some projections suggest that by the year 
2020 depression will be among the highest ranked causes of disability, second only 
to ischemic heart disease. Depression tends to be a recurrent disorder. Indeed it has 
been estimated that up to 85% of patients with depression experience a depressive 
relapse.2 Furthermore patients who are left with residual symptoms of depression have 
an increased risk of recurrence and of future episodes of depression.3 Recent treatment 
outcome and long-term follow-up studies of patients with an index episode of illness 
show that complete elimination of symptoms ie, remission should be the primary goal 
of any form of treatment. Elimination of symptoms has been shown to be associated 
with diminished risk of relapse.4
The goal of continuation treatment is to eliminate residual symptoms, restore 
social functioning and to prevent relapse of depression.5 The degree to which Drug Design, Development and Therapy 2010:4 20
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antidepressant medications are capable of achieving each 
of these goals is mixed and is perhaps most readily dem-
onstrated for relapse prevention. This can be demonstrated 
by alternative methodological approaches, such as continu-
ing open treatment to determine rates of relapse. Clearly 
a more rigorous evaluation method is to randomly assign 
patients who have achieved remission of depression, in 
a double-blind manner, to either placebo or to continue 
the dose of medication that initially achieved the desired 
response. Time to an a priori-defined relapse criterion can 
then be measured in both groups and the statistical differ-
ences assessed from Kaplan–Meier survival analysis. Using 
this general methodological approach the effectiveness for 
relapse prevention of most classes of antidepressants has 
been demonstrated.
In a meta-analysis of 31 studies involving 4410 sub-
jects continuing treatment with antidepressants reduced 
the chance of relapse by 70% compared with cessation 
of treatment.6 The treatment effect persisted for up to 
36 months. Thus tricyclic antidepressants have been clearly 
demonstrated to prevent relapse. Controlled clinical trials 
have established the effectiveness of amitriptyline,7,8 imip-
ramine9–11 nortriptyline12 and desipramine13 as well as the 
monoamine oxidase inhibitor phenelzine.14,15 The duration of 
these studies varied from 16 weeks to three years and each 
demonstrated a superiority of the active drug over placebo 
in preventing relapse. Similar double-blind evaluations have 
been performed for the selective serotonin reuptake inhibi-
tors (SSRIs) fluoxetine16,17 sertraline,18,19 paroxetine,20–22 
citalopram,23,24 and escitalopram.25 Generally SSRIs are 
treatments of choice for continuation therapy due to their 
better tolerability compared to tricyclic antidepressants and 
monoamine oxidase (MAO) inhibitors.26 With the develop-
ment of the serotonin–noradrenaline reuptake inhibitor 
(SNRI) antidepressants, there is an emerging literature on 
their use for continuation therapy. Thus milnacipran has 
demonstrated efficacy in the continuation phase of treat-
ment superior to placebo.27 Recently, venlafaxine has dem-
onstrated superiority over placebo for relapse prevention at 
both one year28 and two year29,30 follow-up periods.
The need for continuation therapy of major depression 
to maintain clinical response has been clearly demonstrated. 
Relapse of depression has been shown to occur in patients 
remitted from depression when switched to placebo or if 
treatment is discontinued. It is incumbent then on any new 
treatment to establish its credentials in this area. Acute treat-
ment trials are often the focus of attention for the purposes 
of registration of new medications with the appropriate 
authorities. Efficacy of new treatments in continuation 
therapy is often poorly established.
Overview of pharmacology and 
pharmacokinetics of duloxetine
Duloxetine is a dual serotonin (5HT) and noradrenaline 
(NE) reuptake inhibitor31,32 with little affinity for a range of 
other neurotransmitter receptors.33 Human in vitro studies in 
healthy volunteers suggest that both serotonin and noradrena-
line reuptake may account for the antidepressant activity of 
duloxetine.34,35 Duloxetine exhibits linear pharmacokinetics 
with an elimination half-life in the range of 7 to 27 hours.36 
It is highly protein-bound (90%) and extensively distributed 
to tissues. Duloxetine is eliminated through hepatic metabo-
lism involving CYP2D6 and CYP1A2.37
Duloxetine in acute treatment  
of major depression
The efficacy of duloxetine in acute treatment of major 
depressive disorder has been reviewed recently.38 Duloxetine 
is more effective than placebo and at least as effective as 
other established antidepressants (fluoxetine, paroxetine, 
escitalopram, venlafaxine). A database of 17 randomized 
controlled acute trials of duloxetine in adult MDD was 
subjected to meta-analysis with random effects modeling.38 
Response rates (reduction of baseline HAM-D by 50%) 
for duloxetine were 48.8% to 59.6% and for placebo were 
35.0% to 42.2%. This gave an average of 40% superiority 
of duloxetine over placebo. In the published trials remission 
rates for duloxetine ranged from 23% to 54%, based on the 
last-observation-carried-forward analysis, compared to 15% 
to 30% for placebo-treated patients. Analysis of comparative 
data did not establish any meaningful clinical differences in 
efficacy from SSRI antidepressants.
Efficacy of duloxetine  
in continuation treatment
Clinical trials undertaken to examine the efficacy of 
duloxetine in continuation treatment of major depressive 
disorder are summarized in Table 1. Six main studies were 
conducted in patients who met either Diagnostic and Sta-
tistical Manual of Mental Disorders, 4th edition (DSM-IV) 
or DSM-IV-TR criteria for the disorder. (A seventh study, 
also summarized in Table 1, was an analysis of a subgroup 
of elderly patients from a previous trial). Duloxetine was 
used for up to 52 weeks in one study while the remaining 
studies were conducted over 24 or 26 weeks of treatment. Drug Design, Development and Therapy 2010:4 21
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Table 1 Continuation studies of duloxetine in major depressive disorder
Design 
 
Subjects, age,  
dose, length  
of treatment
Outcome  
measures 
Statistical  
analysis 
Efficacy 
 
Authors 
 
Open label 928F, 351M 
(18−87 y) 120 mg/day  
52 weeks
HDrS BDrS  
CGi-S  
PGi-i Sheehan
MMrM-ANOvA Change from baseline  
(P  0.001) all measures; 
81.8% remission at end-point
raskin et al39
Open label** 72F, 29M 
(65−87 y)
HDrS BDrS  
CGi-S PGi-i  
Sheehan
MMrM-ANOvA Change from baseline on all  
measures (P  0.001); 72.3%  
remission at end-point
wohlreich et al40
Double blind run-in;  
continuation in responders
267F, 100M (18 y) 
DUL 80 mg/day 
DUL 120 mg/day PAr  
20 mg/day PBO 26 weeks
HDrS MADrS  
HArS CGi-S  
PGi-i vAS
Kaplan–Meier Longer time to loss of  
response for all active drugs  
compared to PBO (P  0.05)
Detke et al45
Open label 12 week run-in;  
responders randomized  
to DUL or PBO
202F, 76M (18 y) 
60 mg/day 26 weeks
HDrS CGi-SvAS Kaplan–Meier;  
ANCOvA
relapse 23% DUL vs 39% PBO  
(P  0.05); time to relapse  
shorter on PBO (P  0.005)
Perahia et al43
Double-blind, parallel  
group study
212F, 83M (18−73 y) 
DUL 60 mg/dayeSC  
20 mg/day 24 weeks
MADrS HDrS  
CGi-S CGi-i HArS  
Sheehan
ANCOvA Mean change in MADrS 21.7  
DUL, 23.4 eSC (NS);  
Significant decline in MADRS  
over time (P  0.05)
wade et al46
Open label extension  
study
126F, 51M (43.7 ± 11.6 y) 
DUL 60–120 mg/day  
Up to 623 days
HDrS CGi-S No formal analysis HDrS did rise above 7  
throughout the extension  
phase.
Dunner et al41
Double-blind, placebo 
controlled study 
 
 
 
291F, 122M (47.4 ± 13.0 y) 
DUL 60–120 mg/day 
PBO 52 weeks 
 
 
HDrS CGi-S PGi-i  
SF-36 Sheehan 
 
 
 
Kaplan–Meier;  
MMrM ANOvA  
 
 
 
improvements in depression  
ratings from open phase  
maintained through  
continuation for DUL; DUL  
patients had longer time to  
relapse than PBO (P  0.001).
Perahia et al44 
 
 
 
 
Notes: *Patients in the studies met either DSM-iv or DSM-iv-Tr criteria for major depressive disorder; ** This study was a reanalysis of data from the raskin and colleagues39 
study for the elderly (aged  65 years) population.
Abbreviations: DUL, duloxetine; eSC, escitalopram; PAr, paroxetine; PBO, placebo; BDrS, Beck depression rating scale; CGi-i, Clinical Global impression Scale–improvement; 
CGi-S, Clinical Global impression Scale–Severity; HDrS, Hamilton Depression rating Scale; HArS, Hamilton Anxiety rating Scale; PGi-i, Patient Global impression Scale–
improvement; Sheehan, Sheehan disability scales; vAS, visual analog scale.
In one naturalistic study duloxetine was administered for 
up to 623 days.
Open evaluations
The efficacy of duloxetine administered over a maximum 
period of 52 weeks for the treatment of major depressive 
disorder (MDD) was investigated in an open-label trial.39 To 
be eligible for admission to the study patients had to meet 
the DSM-IV criteria for MDD and have a Clinical Global 
Impressions Scale (CGI-S) score of 3 at screening and base-
line visits. There were no eligibility criteria in terms of the 
severity of depression at baseline as rated with the Hamilton 
Depression Rating Scale (HAM-D). The study was conducted 
at eight sites in North and South America. Patients received 
duloxetine 40 to 60 mg twice daily with the dose adjusted 
according to the physician’s judgment of tolerability. Efficacy 
of treatment was assessed using the CGI-S, HAM-D 17 item 
scale, the Beck Depression Inventory, and the Patient Global 
Impression–Improvement scale (PGI-I). Quality of life was 
evaluated using the Sheehan Disability Scale. Outcomes 
were assessed at weeks 6, 28, and 52 or earlier if the patient 
discontinued treatment. PGI-I and CGI-S were evaluated at 
all visits. Response and remission were defined on the basis 
of a decline from baseline of the HAM-D score of 50% or 
more (response) or 7 (remission). A total of 1279 patients 
entered the study (72.6% female) of whom 553 (43.2%) 
completed 52 weeks of treatment. After two weeks of treat-
ment those patients unable to tolerate 80 mg/day of duloxetine 
were discontinued. Of the patients who did not complete 
the 52 weeks of treatment, 17% dropped out due to adverse 
events, 6.6% due to noncompliance, and 5.9% for lack of 
efficacy. The remainder of the patients who dropped out of the 
study did so for personal reasons (10.2%), protocol violations 
(3.1%), or were lost to follow-up (9.3%), or for other reasons Drug Design, Development and Therapy 2010:4 22
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(5.7%). The main adverse events associated with dropping out 
of the study were nausea, somnolence, vomiting, diarrhea, 
hypomania, and hypertension. The HAM-D scale showed a 
highly statistically significant decline from baseline at all 
measurement times (P  0.001; repeated measures, analysis 
of variance [ANOVA]). The change in rating was also clini-
cally significant falling from a mean of 22.5 at baseline to 
9.3 at week 6, 5.9 at week 28, and 5.0 at week 52. Factors of 
the HAM-D scales were also significantly reduced over time 
as were the Beck Depression Inventory scale and the Shee-
han disability sub-scales. Rates of response and remission, 
estimated using the last-observation-carried-forward (LOCF) 
were 71% and 60%, respectively. Probability estimates were 
performed for response and remission with 62.9% and 50.8% 
observed at week 6, respectively. These increased with time 
in treatment to 84.3% and 75.6% at week 28 and 89.1% and 
81.8% at week 52. Although an open evaluation, the study 
suggests that continuation treatment of depression with 
duloxetine is capable of achieving remission for a substantial 
number of patients.
For patients aged 65 years or more who took part in this 
open evaluation a subgroup analysis was undertaken.40 At 
the beginning of the continuation treatment phase there were 
101 patients (mean age 71.9 years). In general the clinical 
efficacy results were not different from those obtained when 
the total group was analyzed. Thus there were statistically 
significant improvements in the HAM-D 17-item total score 
from baseline as well as in both the clinician (CGI-S) and 
patient (PGI-I) rated measures of improvement. Response 
rates (defined as noted above for this study) at weeks 6, 28, 
and 52 were 62.9%, 84.9%, and 89.4%, respectively. The 
corresponding remission rates (see earlier definition for the 
study) at these times were 41.4%, 69.8%, and 72.3%, respec-
tively. In this older sub-group, duloxetine maintained clinical 
response in the long term and was not distinguishable from 
the responses observed in patients aged 18 to 64 years. In this 
elderly sub-group discontinuation due to adverse events in 
this sub-group were 26.7% of patients which is somewhat 
higher than the group as a whole (17%). The main adverse 
events associated with withdrawal were somnolence (4.0%), 
dizziness (3.0%), diarrhea (2.0%), hypertension (2.0%), and 
vomiting (2.0%). Another 5.0% of patients withdrew due to 
noncompliance while 9.9% discontinued due to personal or 
other reasons. Most discontinuations (66.7%) occurred within 
the first two weeks of initiation of treatment.
Further evidence for the efficacy of duloxetine in con-
tinuation treatment was obtained from a naturalistic study.41 
In this multicenter trial, patients met DSM-IV criteria for 
MDD and had a HAM-D total score of 15 and a CGI-S 
score of 4 at baseline. Subjects received 30 or 60 mg/day 
of duloxetine in the first week of treatment and thereafter the 
dose could be titrated to a maximum of 120 mg/day. Subjects 
who completed 12 weeks of treatment were eligible to enter 
the continuation phase. The results of the open 12-week study 
were reported separately.42 In this phase of the study response 
was defined as a reduction of 50% or more from baseline of 
the HAM-D score and remission as a HAM-D total score 7. 
These criteria were used throughout the continuation phase. 
Patients were followed on a monthly basis after the acute phase 
of the study. A total of 177 patients commenced the exten-
sion phase and the mean duration of treatment in this phase 
was 305 days with a range of 4 to 623 days. Throughout the 
extension phase the mean HAM-D score remained below 7. 
Thus the data provide evidence for the continuing efficacy of 
duloxetine over extended periods. For the patients entering 
the extension phase, 119 began as remitters of depression, 
27 as responders, and 31 as nonresponders. Generally remit-
ters remained in remission throughout the extension phase 
with only 16 patients (13%) becoming nonresponders. For 
initial nonresponders, 16 patients (52%) became remitters or 
responders while for the initial responders, 11 patients (41%) 
became remitters, and 9 (33%) became nonresponders. Dur-
ing the continuation phase of treatment 21 patients (11.9%) 
discontinued treatment due to adverse events. Of these patients 
11 had events which either worsened during the continuation 
phase or were ongoing and did not improve. For the other 
patients, new events leading to discontinuation were creatine 
phosphokinase (CPK) increased, hypertension, hypomania, 
intentional self injury, rash, suicidal ideation, weight gain, 
nephrolithiasis, and babesiosis.
Placebo-controlled, relapse  
prevention studies
Prevention of relapse of major depressive disorder provides 
superior evidence for the efficacy of a treatment in this condi-
tion. Thus a relapse prevention study was performed in out-
patients who had responded to 60 mg daily of duloxetine in an 
open evaluation.43 In the open phase of the study 533 patients 
were treated with duloxetine and those who responded at 
week 12 were randomly allocated in a double-blind manner 
to either continue duloxetine or to receive placebo. For the 
open phase response to medication was defined as a HAM-D 
score of 12 and a CGI-S score of 2. Furthermore, patients 
should also no longer have met DSM-IV criteria for MDD. 
Patients were then treated for up to 26 weeks. Re-emergence 
of depressive symptoms was defined as a HAM-D score Drug Design, Development and Therapy 2010:4 23
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12, while relapse was defined as a CGI-S score of 2 
points compared to that at week 12 and meeting the MINI 
criteria for MDD at two consecutive visits at least two weeks 
apart. Of the original 533 patients, 136 continued to receive 
duloxetine, and 142 to receive placebo. The primary efficacy 
analysis compared the time from randomization to relapse 
between the two groups using the log-rank test. The two 
groups for the continuation phase of treatment were well 
matched in terms of age, gender distribution and severity 
of illness on both the HAM-D and CGI-S scales. Patients 
receiving duloxetine took a statistically significantly longer 
time to relapse than those receiving placebo (P  0.005, 
Kaplan–Meier). Based on the protocol criteria for relapse 
28.5% of placebo-treated patients relapsed compared to 
17.4% of duloxetine-treated patients over this time frame 
(P  0.05). When assessed by the investigator alone to have 
relapsed, 43.1% of placebo compared to 21.9% of dulox-
etine patients met clinical judgment criteria (P  0.001). 
Changes in the HAM-D scale over the continuation period 
were evaluated as a secondary criterion of efficacy. Patients 
treated with duloxetine were less likely than those treated 
with placebo to have a deterioration in their total 17-item 
score (P  0.01; ANOVA). In addition to the total HAM-D 
score factors derived from the scale also showed statistical 
and clinically relevant superiority of duloxetine over pla-
cebo. The study shows that duloxetine maintains its clinical 
efficacy in the treatment of MDD over an extended time 
frame. In the continuation phase there were no statistically 
significant differences between duloxetine- and placebo-
treated patients for the rates of adverse events. A total of 
five patients discontinued duloxetine in the extension phase 
due to adverse events: anxiety, cholelithiasis, spastic colon, 
ejaculation failure, and gastroesophageal reflux were reported 
by one patient each. A similar number of placebo-treated 
patients discontinued treatment. In the group randomized to 
duloxetine, one patient discontinued due to lack of efficacy, 
11 due to their own decision, and a further 16 patients due 
to protocol violations or were lost to follow-up.
A more recent study reported on prevention of depres-
sive recurrences in a group of subjects meeting DSM-IV 
criteria for MDD.44 An additional criterion for entry into 
the study was that patients should have had at least three 
episodes of depression in the past five years. In this multi-
centre trial after open treatment for up to 34 weeks with 
60–120 mg/day of duloxetine (administered once daily), 
patients meeting response criteria were randomly assigned 
to placebo or duloxetine for up to 52 weeks in a double-blind 
maintenance phase. Response criteria were HAM-D score 
9, CGI-S 2, and no longer meeting DSM-IV criteria 
for MDD. The primary outcome measure was the time to 
recurrence of a depressive episode. Criteria for recurrence 
were based on any of the following being met: CGI-S score 
4; meeting DSM-IV criteria for MDD; three consecutive 
visits meeting re-emergence criteria (ie, CGI-S 4 but not 
fulfilling DSM criteria for MDD) or 10 total re-emergence 
visits; withdrawal due to lack of efficacy. Of the 514 patients 
who initially entered the study, 288 were eligible for the 
maintenance phase. Both time to depressive recurrence and 
the time to a 50% increase in depressive symptoms (based on 
HAM-D total score) was significantly longer in duloxetine-
treated than in placebo-treated patients (P  0.001). In the 
double-blind phase 33.1% of patients receiving placebo 
experienced recurrence of depression whereas 14.1% of 
patients receiving duloxetine had a recurrence of depression 
(P  0.001). It can be concluded that duloxetine is useful 
in the prevention of recurrence of depressive episodes in 
patients prone to recurrence. The proportion of patients who 
discontinued in the maintenance phase due to adverse events 
was 2.1% in the placebo group and 4.1% in the duloxetine 
group. In this phase of the study there were no statistically 
significant differences between groups for treatment emer-
gent adverse events.
Placebo-controlled, comparative  
relapse prevention studies
Duloxetine was compared to paroxetine and placebo in the 
acute and long-term treatment of major depressive disorder.45 
Following an 8-week double-blind, placebo-controlled study 
patients who had responded to treatment were continued 
for up to six months on blinded medication. Response was 
defined as a 30% decline in baseline HAM-D total score. 
All patients met DSM-IV criteria for MDD which was con-
firmed by the MINI interview schedule. In the initial study 
367 patients were randomly allocated on a 1:1:1:1 basis to 
receive duloxetine 80 mg/day, duloxetine 120 mg/day, par-
oxetine 20 mg/day, or placebo (approximately 90 per group). 
The primary efficacy variable was the HAM-D 17-item scale 
with secondary outcome measures obtained from the factors 
of the HAM-D scale, the Montgomery–Åsberg Depression 
Rating Scale (MADRS) scale, HAM-A, Visual Analog Scale 
(VAS), CGI-S, and PGI-I scales. In addition the Sheehan 
Disability Scale and the Somatic Symptom Inventory were 
also assessed at baseline, weeks 1, 2, 4, 6, and 8. In the acute 
phase all active treatments were superior to placebo for all 
outcome measures. For the primary outcome variable, dif-
ference between baseline and end-point HAM-D total score, Drug Design, Development and Therapy 2010:4 24
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both doses of duloxetine and paroxetine were superior to 
placebo (P  0.001; analysis of covariance [ANCOVA]). 
Subsequent to the acute phase a total of 273 patients entered 
the continuation phase. During this phase of treatment loss of 
response was defined as the first visit at which the HAM-D 
showed a less than 30% reduction from the acute baseline 
score. This criterion varies from that used in the majority of 
studies where a score on the HAM-D scale is usually taken as 
a cut-off for relapse. Given that the mean HAM-D at baseline 
across the groups was ∼20 then the cut-off for relapse would 
have been a HAM-D score of ∼14. This is a more lenient 
criterion than in other trials but on the other hand allows for 
individual differences in starting baseline scores. Statistically 
significant differences between treatments were assessed by 
means of a Kaplan–Meier estimate. All three active treat-
ment groups had a longer time to loss of response than did 
placebo (P  0.005; log-rank test). Remission (HAM-D total 
score 7) rates at the end of the acute study were 46% for 
duloxetine 80 mg/day, 52% for duloxetine 120 mg/day, 44% 
for paroxetine, and 30% for placebo. It is not clear for the 
study whether these remission (or response) rates increased 
with continued treatment. Nevertheless the study does sup-
port continuing efficacy of duloxetine during ongoing treat-
ment. The proportion of patients who discontinued due to 
adverse events was similar across all four treatment groups: 
6.9% placebo; 4.3% duloxetine 80 mg/day; 6.7% duloxetine 
120 mg/day; 2.9% paroxetine.
A similar study compared the efficacy of acute and 
continuation treatment with duloxetine and escitalopram in 
outpatients with MDD.46 Patients in this study met DSM-IV-
TR criteria for MDD as confirmed by the MINI interview. 
In addition patients met the severity criteria of a MADRS 
total score of 26 and a CGI-S score of 4. Patients were 
randomly allocated, on a double-blind basis and a 1:1 ratio, 
to treatment with either duloxetine 60 mg/day or escitalo-
pram 20 mg/day. The duration of the study was 24 weeks. 
Efficacy was assessed at baseline and weeks 1, 2, 4, 8, 12, 
16, 20, and 24 using the MADRS scale as the primary out-
come measure. The mean change in MADRS score from 
baseline to week 24 based on the intent to treat population 
was used to assess efficacy. The last observation carried 
forward was used to account for missing data. An analysis 
of covariance was used to assess statistical significance 
of the change. Secondary efficacy measures included the 
HAM-D scale, CGI-S, and the HAM-A scale. Remission was 
defined as a MADRS 12 or HAM-D 7. Response was 
defined as a decline from baseline of 50% in the MADRS 
or HAM-D score. A total of 294 patients were enrolled 
in the study (151 duloxetine, 143 escitalopram) whereas 
the intention-to-treat (ITT) data set was 287 patients (146 
duloxetine, 141 escitalopram). There were few statistically 
significant differences between the two drugs at any time 
point throughout the study. At week 8 remission rates were 
48% for duloxetine and 56% for escitalopram (nonsignifi-
cant [NS]) while at week 24 the respective rates were 70% 
and 73% (NS). The study again supports the notion of the 
efficacy of duloxetine in the long-term treatment of MDD. 
Significantly more patients withdrew from the duloxetine 
(17%) than the escitalopram (9%) as a result of adverse 
events. Nausea, agitation, and insomnia were the main events 
leading to withdrawal from the study.
Safety of duloxetine
Apart from efficacy the major concern with continuation 
treatment of any medication is its safety and the occurrence 
of serious adverse events. The safety of duloxetine has been 
the subject of reviews using pooled data.47,48 In each of the 
studies described above the general tolerability of duloxetine 
was evaluated. The emergence of adverse events serious 
enough to warrant the concern of authorities and which may 
lead to the withdrawal of an agent are not usually apparent 
until the post-marketing phase. There is no indication from 
the clinical studies so far conducted with duloxetine that any 
rare life-threatening events have occurred.
Adverse events
For patients who underwent treatment beyond the short-term, 
new emergent adverse events were generally diminished 
compared to the acute phase of treatment. For each of the 
trials reviewed emergent adverse events during the continu-
ation phase are summarized in Table 2. The consistency with 
which events were reported varied from study to study but 
in most cases new adverse effects which emerged in the 
continuation phase were tabulated. The exception was the 
study by Perahia et al43 where no tabulation of events was 
available but a summary of events leading to discontinuation 
of treatment was provided.
In the one year open-label trial,39 the incidence of all 
events occurring within the first eight weeks of treatment were 
markedly reduced over the next 44 weeks. The most common 
side effect in the first eight weeks of treatment was nausea, 
experienced by 31.8% of patients. From week 9 to 52 the 
incidence of nausea was reduced to 3.4% of patients treated. 
Reductions of a similar magnitude were noted for other adverse 
events, eg, somnolence 27.7% to 2.8%, insomnia 24.9% to 
7.3%, headache 22.4% to 10.0%, dry mouth 22.1% to 2.7%, Drug Design, Development and Therapy 2010:4 25
Continuation treatment of major depressive disorder Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
constipation 18.8% to 3.3%. Tolerance to the side effects of 
duloxetine clearly develops with continued treatment. Serious 
adverse events were reported by 64 patients in this study and 
included suicidal ideation (7), suicide attempt (7), accident 
(3), hip fracture (3), angina (2), anxiety (2), cholelithiasis 
(2), confusion (2), depression aggravated (2), mania (2), and 
overdose (2). Seventeen percent of patients discontinued treat-
ment due to an adverse event during the continuation phase. 
From this same study data for patients aged over 65 years was 
reanalyzed with respect to the adverse event profile.40 In this 
older sub-population (n = 101) all treatment emergent adverse 
events were diminished in weeks 9 to 52 compared to weeks 
1 to 8. Thus nausea was reduced from 28.7% to 0%, dizziness 
from 26.7% to 5.0%, somnolence 21.8% to 1.0%, dry mouth 
from 15.8% to 4.0%, and insomnia from 14.9% to 7.9%. 
Older patients tended to report statistically significantly less 
insomnia and headache than younger patients. The incidence 
of other adverse events was not different between elderly and 
young patients. There were single reports of syncope and pos-
tural hypotension in the elderly subgroup, while two patients 
experienced falls during the study.
In the open evaluation conducted by Dunner and col-
leagues, data were analyzed for new or worsening adverse 
events during the extension phase.41 Few patients reported 
new clinically significant adverse events. The main new 
events reported were fatigue (9.0%) and hyperhidrosis 
(4.5%). The time to onset of these events was not analyzed.
In the six month continuation study,45 no new treatment 
emergent adverse events were reported by more than 5% of 
patients in the continuation phase. The main treatment emer-
gent events during continuation were diarrhea, headache, 
nausea, insomnia, anxiety, dizziness, flatulence, and pain. 
These were reported by less than 4% of all patients treated 
and were dose dependent. Three patients died in this phase of 
the study due to suicide (1 duloxetine 120 mg/day; 1 placebo) 
or pulmonary edema (duloxetine 80 mg/day).
Statistically significant differences in the rate of adverse 
events reported between duloxetine and placebo were not 
observed during a prevention of relapse study conducted over 
26 weeks of treatment.43 No further details of the adverse 
events were reported in this study except for events leading 
to discontinuation of study drug as noted above.
In a double-blind, dose escalation study patients with 
DSM-IV major depressive disorder were treated with dulox-
etine according to a dosage regimen that was increased to 
120 mg/day over the first three weeks and then stabilized 
for a further four weeks.49 This period was followed by an 
open-label, six-week stabilization phase during which the 
duloxetine dose was adjusted to the optimal maintenance 
dose. Following the stabilization period patients could 
Table 2 emergent events during continuation treatment with duloxetine
Event Raskin Wohlreich Dunner Detke≠ Wade* Perahia (2)
Nausea 3.4 0 Nr Nr 31.4 Nr
Somnolence 2.8 1.0 Nr Nr 1.3 Nr
insomnia 7.3 7.9 5.6 2.7 12.6 4.8
Headache 10.0 5.9 1.1 2.7 16.6 8.9
Dry mouth 2.7 4.0 Nr Nr 13.2 Nr
Constipation 3.3 5.0 Nr Nr 8.6 Nr
Dizziness 6.4 5.0 10.7 2.7 15.9 3.4
Sweatiness 4.3 4.0 1.7 Nr 7.3 Nr
Diarrhea 3.8 5.9 Nr 4.0 7.3 Nr
Tremor 1.3 2.0 1.7 Nr Nr Nr
Anxiety 7.3 3.0 2.2 2.7 Nr Nr
Fatigue 3.4 4.0 2.2 Nr 11.3 5.5
Decreased appetite 0.9 1.0 Nr Nr Nr Nr
Anorexia 1.2 3.0 1.1 Nr Nr Nr
vomiting 2.6 3.0 3.9 Nr 7.3 Nr
Back pain Nr 2.0 7.3 Nr Nr 8.9
Other pain Nr 2.0 4.5 2.7 Nr Nr
Notes: For the study by Perahia and colleagues,43 a list of adverse events and incidences was not reported. ≠Data from treatment with 120 mg/day of duloxetine; *Adverse 
events in the extension phase were not separated from the acute phase.
Abbreviation: Nr, no reports for this individual event in the published data.Drug Design, Development and Therapy 2010:4 26
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continue treatment depending on clinical need. The primary 
objective of the study was to assess safety and tolerability of 
duloxetine. A total of 81 patients entered the extension phase. 
During this phase the main emergent adverse events were 
upper respiratory tract infection (13.1%), headache (10.7%), 
insomnia (10.7%), anxiety (9.5%), increased weight (9.5%), 
nasopharyngitis (8.3%), constipation (7.1%), hyperhidrosis 
(7.1%), abnormal dreams (6.0%), and sinusitis (6.0%). The 
rate of discontinuation due to adverse events in this phase 
of the study was 11.9% whereas 21.4% discontinued due to 
lack of efficacy, 15.5% were lost to follow-up, and 15.5% 
due to patient decision or protocol violations.
Treatment emergent adverse events occurred with a 
similar frequency in placebo- and duloxetine-treated patients 
during relapse prevention over 52 weeks.44 Headache (8.9%), 
back pain (8.9%), nasopharyngitis (6.2%), influenza (3.4%), 
insomnia (4.8%), dizziness (3.4%), and fatigue (5.5%) were 
reported as events associated with duloxetine administration. 
The difference in incidence for the same events in placebo-
treated patients was not statistically significant.
Adverse events emerging specifically in the continuation 
phase of treatment with either duloxetine or escitalopram 
were not available, as the data were compared across the 
entire 24 week period.46 The only statistically significant dif-
ference between treatments was for insomnia which occurred 
more frequently with duloxetine than with escitalopram 
(12.6% vs 4.9%). It is not clear whether this difference was 
due to the early phase or continuation phase of treatment.
In summary, duloxetine appears to be well tolerated dur-
ing extended periods of use with tolerance developing to the 
side effects of medication over the course of treatment. The 
main emergent events likely to occur with continued use 
appear to be hyperhidrosis, fatigue, somnolence, insomnia, 
and dizziness.
Clinical laboratory data
Short-term treatment with duloxetine has been associated 
with small increases in liver enzyme values.50 Alkaline 
phosphatase, alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) were all increased compared to 
placebo-treated patients. In the continuation studies reviewed 
here there was sporadic reporting of data for clinical labo-
ratory tests. Statistically significant changes from baseline 
to last observation for some laboratory parameters were 
reported in the open 12 month study.39 However it was noted 
that the mean changes were small compared to baseline val-
ues and was regarded as not clinically significant. The labora-
tory values outside of the normal range were relatively few. 
Furthermore, there did not appear to be any temporal pattern 
of the emergence of these events. Abnormal values tended to 
decline with treatment and mean changes from baseline to 
week 52 were close to zero. None of the changes in values 
were associated with clinical symptoms. Similar findings and 
conclusions were drawn for the elderly subgroup of patients 
in this study analyzed separately.40 Small mean changes in 
laboratory parameters which were not considered clinically 
meaningful were also reported in a placebo-controlled six-
month continuation study.45
No clinically significant or persistent changes in clini-
cal laboratory results were observed in patients treated with 
duloxetine for prevention of relapse of major depression.43 In 
the continuation phase of this study elevations of ALT (n = 7) 
and AST (n = 4) were noted for duloxetine-treated patients. 
The elevated levels resolved spontaneously. No other specific 
laboratory parameter abnormalities were noted in the report. 
Similarly three patients had elevated hepatic parameters (three 
times the upper limit of normal) in a dose escalation study of 
duloxetine.49 No other abnormalities from the extension phase 
of this study were reported. Statistically significant differences 
in the percentage of subjects exhibiting laboratory abnor-
malities between placebo and duloxetine at any time during 
a relapse prevention trial were observed only for bilirubin.44 
Abnormally high levels were observed in the placebo group 
(3.9% vs 0% in the duloxetine group). The mean change 
from baseline to last observation for ALT was significantly 
different between placebo and duloxetine (–0.38 ± 12.5 vs 
2.52 ± 15.4 U/L (P  0.05) but not for any other analyte 
at any time point. Information for laboratory tests was not 
available from the other studies reviewed here.
vital signs and cardiovascular effects
The cardiovascular profile was a particular focus of the 
majority of continuation trials with duloxetine. Mean changes 
in supine and standing blood pressure (BP) from baseline 
to last observation did not change statistically or clinically 
significantly during 52 weeks treatment with duloxetine.39 
There were small increases in supine and standing pulse 
(1.5 and 1.8 bpm) in this study. An analysis of patients who 
were hypertensive at baseline compared to those who were 
nonhypertensive was also performed. Mean changes in 
supine and standing diastolic and systolic BP did not differ 
between hypertensive and nonhypertensive subjects. Dur-
ing treatment, 46 of 1039 patients who were normotensive 
at baseline met criteria for hypertension. Of these patients 
23 returned to baseline BP during continued treatment with 
the drug. Of the 1039 normotensive patients only two had a Drug Design, Development and Therapy 2010:4 27
Continuation treatment of major depressive disorder Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
sustained hypertensive episode (systolic BP 180 mmHg or 
diastolic 110 mmHg). There were no significant changes 
in electrocardiogram (ECG) intervals from baseline. Mean 
change from baseline to last observation in the corrected QT 
interval (QTc) was 0.52 msec, not different from zero. One 
female and one male patient had a treatment emergent QTc 
interval 450 msec. Similar findings were reported for the 
analysis of the elderly sub-group of patients in this study.40 
The rate of potentially clinically significant low values for 
standing BP was 5.2% and for all other BP and pulse read-
ings was 2.5%. Changes in cardiac intervals detected by 
ECG were not clinically significant.
No statistically significant mean changes in baseline to 
endpoint heart rate, systolic and diastolic BP were noted in the 
continued treatment with duloxetine 80 and 120 mg/day for 
up to six months.45 Mean changes in the QTc interval were not 
significantly altered from baseline to endpoint. No patients 
had QTc intervals 500 msec. The cardiovascular profile of 
duloxetine was reportedly similar to that of placebo.43 Small, 
but statistically significant differences, were noted for the 
change in diastolic BP between duloxetine- (60 mg/day) and 
placebo-treated patients (+2 mmHg vs –1 mmHg; P  0.005) 
during this 26 week continuation study. There were no statis-
tically significant mean changes in systolic BP and heart rate 
over the same period. Increases of 1.4 mmHg and 1.1 mmHg 
were noted for supine systolic and diastolic BP respectively in 
a continuation trial of duloxetine for up to two years.49 These 
changes were not statistically significant when compared to 
baseline. Heart rate was increased by 3.1 bpm (P  0.001 
compared to baseline). Mean increase in systolic BP, adjusted 
for baseline, after 1.5 years treatment with duloxetine was 
between 1.3 and 2.2 mmHg.41 For diastolic BP the adjusted 
mean was between –0.1 and 0.5 mmHg. Two patients met 
criteria for sustained hypertension. For pulse the adjusted 
mean increases were between 1.7 and 4.2 bpm.
A more extensive analysis of BP, pulse, and ECG changes 
was performed in a relapse prevention study with duloxetine 
compared to placebo.44 Mean changes in BP and pulse did not 
differ significantly between placebo- and duloxetine-treated 
patients. The mean (± standard deviation [SD]) change in 
systolic BP was 1.5 (±1.0) mmHg and diastolic BP was –0.2 
(±0.7) mmHg for duloxetine-treated patients. Criteria for 
sustained elevations of BP were noted in three duloxetine- 
and two placebo-treated subjects. The QTc interval was not 
different between groups and there were no potentially clini-
cally significant QTc increases at any time in the study. The 
mean change in QTc for duloxetine patients was 1.3 (±1.6) 
milliseconds. Heart rate was increased by 0.2 (±0.95) bpm.
Patients treated with duloxetine for up to 24 weeks had 
nonstatistically significant increases of 1.2 mmHg in systolic 
and 0.3 mmHg in diastolic BP.45 Heart rate was increased by 
2.7 bpm from baseline.
Confirming the generally safe cardiovascular profile of 
duloxetine have been some studies specifically designed to 
address the issue as well as meta-analyses of the clinical 
trial database for major depression and other conditions. 
A particular issue with many psychotropic medications has 
been the association with sudden cardiac death, probably 
as a result of prolongation of the corrected QT interval 
(QTc).51 In healthy female volunteers supra-therapeutic 
exposures to duloxetine were compared in the presence and 
absence of 400 mg moxifloxacin, a drug known to prolong 
QTc interval.52 Mean QTc interval was not prolonged and 
in fact decreased from baseline. At the doses used in this 
study (160 mg and 200 mg bd) duloxetine is unlikely to 
affect cardiac conduction in healthy subjects. Data from 
short term clinical trials suggest that the mean change in 
the QRS width of the electrocardiogram was not clinically 
significant.47
A meta-analysis of the cardiovascular safety of dulox-
etine was performed in more than 8000 patients treated 
with the drug or placebo for up to 36 weeks.47 This safety 
profile was based on vital signs, ECGs and emergent events 
potentially related to cardiovascular effects of the drug. 
Increases in heart rate and decreases in QTc interval were 
more likely to occur in duloxetine-treated patients. How-
ever such changes as were observed were not regarded as 
clinically significant. A prolongation of the QTc interval 
to 500 msecs occurred in one duloxetine-treated patient. 
Mean increases in systolic and diastolic BP were 0.65 mmHg 
and 0.88 mmHg respectively for duloxetine-treated patients. 
There was no evidence for a sustained increase in BP associ-
ated with the use of duloxetine. Adverse events potentially 
related to the cardiovascular system such as palpitations, 
tachycardia, orthostatic hypotension, hypertension and 
peripheral edema occurred in duloxetine- and placebo-
treated patients to similar extents. These events occurred 
with a frequency less than 2%.
Duloxetine at the doses used in the clinical trials would 
appear to have a favorable cardiovascular safety profile.
Body weight
After 52 weeks of treatment with duloxetine, a statisti-
cally significant weight increase of 2.4 kg was noted from 
baseline.39 Using the LOCF data set the mean change 
in weight was 1.1 kg. Analysis of the elderly sub-group Drug Design, Development and Therapy 2010:4 28
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within this study showed a mean weight loss of 0.1 kg 
using baseline to last observation.40 On the other hand, 
using the mixed model repeated measures analysis there 
was a mean weight gain of 0.3 kg. Potentially clinically 
significant weight loss was experienced by three patients 
while potentially clinically significant weight gain was 
experienced by six patients. Weight increased significantly 
in all treatment groups during continuation treatment of up 
to six months.45 For placebo the mean change in weight was 
0.4 (±15.2) kg, for duloxetine 80 mg/day was 1.4 (±15.1) kg, 
duloxetine 120 mg/day 1.9 (±19.2) kg and for paroxetine 
20 mg/day was 1.6 (±16.1) kg. Mean change in body was 
0.9 kg in patients treated with duloxetine for up to two 
years.49 Similarly during 1.5 years of treatment mean weight 
gain depended on whether patients were drug-naïve or had 
received previous treatments.41 Thus for drug-naïve patients 
mean weight gain was 2.54 kg compared with 0.4 kg for 
previously treated patients. A mean weight gain of 0.88 
(±0.36) kg in duloxetine-treated patients was not statisti-
cally different from that of placebo-treated patients during 
relapse prevention.44 Post hoc analysis of the proportion 
of patients with weight gain 7% of baseline showed no 
differences between duloxetine and placebo.
The outcome for weight gain or loss was not reported in 
the other continuation studies.
It can be expected that long-term treatment will result 
in weight gain for some patients. This may be due in part to 
effects of medication but may also be due to the resolution 
of depressive symptoms when appetite is regained.
Sexual function
Sexual dysfunction, which may emerge or worsen during 
the course of treatment, represents a significant clinical 
problem and is common to most, if not all, antidepressant 
medications.53 Treatment emergent sexual dysfunction in 
the relapse prevention study was assessed using the Arizona 
Sexual Experience Scale (ASEX).44 Mean scores on the 
scale tended to improve from baseline for both men and 
women, but not statistically significantly. There were no 
differences between duloxetine and placebo for changes 
from baseline. In the other studies sexual dysfunction was 
recorded as a reported side effect of medication. Decreased 
libido (4.1%), ejaculation failure (2.7%), and erectile dys-
function (2.5%) were reported as side effects of duloxetine 
during a 52 week continuation study.39 For loss of libido 
the relative incidence between male and female subjects 
was not distinguished. Erectile dysfunction (2.4%), delayed 
ejaculation (1.2%), decreased libido (1.2%), and loss of 
libido (1.2%) were reported in a two-year continuation 
study.49
The incidence of treatment emergent sexual dysfunction 
with duloxetine was assessed by pooling data from four 
double-blind, placebo-controlled clinical trials.54 Data from 
two continuation treatment studies, up to 26 weeks, was 
available for the analysis. Sexual function was assessed 
using the ASEX administered at baseline and endpoint. 
In contrast to the experience in the short term, there was 
no difference between duloxetine and placebo for the 
incidence of sexual dysfunction (39.4% vs 35.3%) in 
the continuation phase. In an eight-month double-blind, 
placebo-controlled study in patients with MDD sexual 
functioning was assessed using the Changes in Sexual 
Functioning Questionnaire (CSFQ).55 In the short-term 
(up to eight weeks) both duloxetine and escitalopram had 
significantly higher incidences of sexual dysfunction than 
placebo, for patients who did not meet criteria at baseline 
for sexual dysfunction. At eight months of treatment, emer-
gent sexual side effects were 33.3% for duloxetine, 43.6% 
escitalopram, and 25.0% for placebo. These differences 
were not statistically significantly different. Patients who 
recovered from MDD consistently showed improvements 
in sexual functioning whereas those who did not improve 
tended to show a worsening of function, as measured by the 
CSFQ. In this study there were no statistically significant 
differences between duloxetine and escitalopram discon-
tinuation rates for sexual dysfunction.
While it should be expected that sexual dysfunction is 
likely to be a significant adverse event for many patients, 
this will be confounded by the outcome of the depressive 
episode itself.
Discontinuation emergent events
Abrupt discontinuation was studied after long-term treat-
ment when patients were assessed two weeks after ceasing 
medication.39 The main effects which were reported were 
dizziness (8.3%), anxiety (4.3%), nausea (4.2%), headache 
(3.1%), insomnia (2.9%), and irritability (2.6%). In the 
elderly sub-group analysis for this study the adverse events 
recorded in this phase were dizziness (8.9%), anxiety (7.9%), 
headache (5.0%), and insomnia (5.0%).40 Discontinuation 
adverse events were reported for 23.0% of duloxetine-treated 
patients following abrupt discontinuation of drug after 
a 52-week double-blind, maintenance treatment.44 Three 
serious events, convulsions, hypertension, and hypertensive 
crisis, were experienced by one patient who discontinued 
duloxetine.Drug Design, Development and Therapy 2010:4 29
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Discontinuation was not specifically reported in the other 
studies reviewed as they were designed to assess the efficacy 
of ongoing treatment.
Both the type and the rate of discontinuation emergent 
adverse events appear to be similar in the continuation stud-
ies as those observed after short-term treatment. It seems 
likely that duloxetine should not be abruptly discontinued 
but should be tapered on withdrawal.
Other events
The emergence of suicidal ideation, suicide, and the switch 
into hypomania or mania are significant problems with the 
use of antidepressant drugs in both the short- and long-term. 
Some cases of suicide attempts during therapy with dulox-
etine have been reported.56 Significantly in long term trials 
there have been reports of suicide attempts and the emergence 
of suicidal ideation.39 While these have been estimated to be 
not significantly different from placebo, at least from meta-
analysis of short term studies57 suicide and the development 
of suicidal ideation is an ever present risk in the treatment 
of depression.
Data from a pooled analysis of eight acute phase tri-
als58 showed that the emergence of mania or hypomania in 
patients treated with duloxetine was low (0.2%). Whether 
this translates to continuation treatment is not clear, but two 
cases of mania were reported during one year of treatment.39 
The emergence of manic episodes in other continuation trials 
was not specifically reported.
Conclusions
Duloxetine has demonstrated efficacy in the treatment of 
major depressive disorder in continuation studies for up 
to one year or more. The medication maintains its short-
term effectiveness during continued treatment. Importantly 
controlled studies suggest that duloxetine is able to prevent 
relapse significantly better than placebo, which attests to 
the efficacy of the drug for continuation treatment. Further-
more, a study in patients prone to relapse of their depressive 
episodes showed duloxetine to be effective in maintenance 
treatment. Although the current data base for continuation 
treatment is relatively circumscribed, there is sufficient evi-
dence to be assured that in patients who initially respond to 
the medication, efficacy, measured in terms of remission of 
an index episode of depression, is continued in the longer 
term. Tolerance to the majority of side effects tends to develop 
with continued treatment. However, as with all medications 
continued pharmacovigilance needs to be undertaken to 
monitor for rare, but potentially dangerous, events. On cur-
rent levels of exposure there is no evidence for these rare life 
threatening events, but clearly confidence in this statement 
increases with greater exposure.
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